Skip to main content
. 2012 Jan 1;13(1):1–13. doi: 10.4161/cbt.13.1.18438

Figure 1.

Figure 1

Druggable signaling pathways in endometrial cancer. Abbreviations: EGF, epidermal growth factor; IGF, insulin-like growth factor; TGFα, transforming growth factor α; FGF, fibroblast growth factor; HER, human epidermal growth factor receptor; EGFR, epidermal growth factor receptor; IGFR1, insulin-like growth factor receptor 1; FGFR2, fibroblast growth factor receptor 2; ATP, adenosine triphosphate; AMP, adenosine monophosphate; VEGF, vascular endothelial growth factor, PDGF, platelet-derived growth factor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; GRB2, growth factor receptor-bound protein 2; RAS, rat sarcoma gene; Raf, V-raf-1 murine leukemia viral oncogene homolog 1; MEK, mitogen activated protein kinase kinase; ERK, mitogen activate protein kinase; SRC, V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog; IRS, insulin receptor substrate; PI3K, phosphatidylinositol 3 Kinase; PTEN, phosphatase and tensin homolog deleted on chromosome 10; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-triphosphate; AKT, v-akt murine thymoma viral oncogene homolog 1; PKA, protein kinase A; LKB1, liver kinase B1; AMPK, adenosine monophosphate kinase; mTORc, mammalian target of rapamycin Complex.